15-year survival estimates were calculated using the PREDICT Prostate algorithm, with coefficients for each of the above parameters used alongside baseline hazards to calculate prostate cancer -specific mortality (PCSM) and all-cause mortality (ACM) in a competing risk model. Discrimination was assessed using Harrells concordance(c)-index for rightcensored data. Calibration was evaluated using actual follow-up to censorship at 15 years. Data analyses were performed in Stata (TX, USA) and R.
INTRODUCTION AND OBJECTIVES: Pelvic lymph node dissection (PLND) is recommended for men at risk for lymph node involvement at the time of radical prostatectomy (RP) yet is frequently omitted. We aimed to examine the probability of PLND based on clinical risk status, and to evaluate the impact of increasing lymph node yield on cancer detection rate across risk strata, with particular interest at the extremes of risk.
METHODS: We queried the National Cancer Database to identify patients with clinically localized PCa who underwent RP as their primary treatment from 2004 to 2014. We extracted clinical and sociodemographic variables. Risk status was assessed using UCSF Cancer of the Prostate Risk Assessment (CAPRA) score. We fit conditional logistic regression models to estimate likelihood of PLND and incremental value of increasing lymph node count by risk strata. We also evaluated the association of PLND and increasing lymph node count with 30-day readmission RESULTS: We identified 698,728 men with Prostate Cancer treated with RP including 380.201 (54.41%) with PLND. Mean age at diagnosis was 62.6. PLND was omitted (Nx) in 56.1%, 31.4%, and 24.7% of patients with low, intermediate and high CAPRA-risk disease, respectively. Adjusting for clinical and pathologic factors, treatment in a community versus academic hospital (OR[1.62, 95% CI 1.59-1.66; P <0.001) and black race (OR[1.13, 95% CI 1.09-1.17, P: 0.01) was associated with increased odds for pNx status. Increasing lymph node count was independently associated with greater likelihood of detection of lymph node metastasis in all risk strata. In patients at the lowest spectrum of risk (CAPRA-0), greater reported lymph node yield remained associated with detection of metastasis (relative to 0-10, 11-20 nodes: OR: 3.28, 95% CI 3. 06-3.53, P<0.001; 20-30 METHODS: OSNA is based on a short homogenization step and subsequent automated amplification of CK19 mRNA directly from the sample lysate, with results available in ca. 30 minutes. In this prospective study (DRKS00011401), OSNA was performed on 574 SLNs from 65 intermediate-or high-risk PCa patients (PSA >10 ng/ml and/or Gleason-score !7). Fresh SLNs were cut into 2mm thick slices. Alternate slices were used for OSNA (frozen samples) and histopathology (paraffin embedded; H&E staining and CK19 and CK AE1/AE3 immunohistochemistry). Using the breast cancer cutoff value for detecting LN metastasis (>250 CK19 mRNA copies/ml) samples were defined as 'negative' or 'positive' and categorized as micrometastases (250-5000 copies/ml) or macrometastases (>5000 copies/ml). The accuracy of OSNA and measure of agreement (Cohen's Kappa coefficient (k)) were evaluated based on histological diagnosis.
RESULTS: Histologically, 74 SLNs were determined to be metastasis positive. The sensitivity of the OSNA assay was 82.4%; specificity was 95.8%. Discordant results were recorded for 34 of the 574 resected SLNs resulting in a concordance of 94.1%. In 21 cases, a positive result was given by the OSNA assay but not by histological examination. 23 of the 34 histologically-negative/OSNA-positive or OSNA-negative/histologically-positive SLNs were classified as micrometastasis. Assuming a possible allocation bias in these cases, the sensitivity would be 93.3%. Overall, the level of agreement was high (k[0.75) .
CONCLUSIONS: This is the first study using OSNA to detect CK19 expression in LN specimens of PCa patients. Initial data indicate that OSNA has at least similar performance in the detection of LN metastases compared with conventional histopathology. OSNA seems to be a promising molecular tool for rapid detection of LN metastases or improvement of intraoperative LN staging combined with sentinelguided lymphadenectomy (LA) (e.g., extended LA in case of positive SLNs) in PCa. In order to verify discordant results, further investigations are required.
